Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: Results from a phase 2, randomized, parallel-arm, open-label study

British Journal of Haematology

Volumn 158, Issue 2, 2012, Pages 274-282

  Forni, Gian Luca ^a   Perrotta, Silverio ^b   Giusti, Andrea ^a   Quarta, Giovanni ^c   Pitrolo, Lorella ^d   Cappellini, Maria Domenica ^e   D'Ascola, Domenico Giuseppe ^f   Borgna Pignatti, Caterina ^g   Rigano, Paolo ^d   Filosa, Aldo ^h   Iolascon, Giovanni ^b   Nobili, Bruno ^b   Baldini, Marina ^e   Rosa, Alessandra ^a   Pinto, Valeria ^a   Palummeri, Ernesto ^a  

^a GALLIERA HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Division of Haematology   (Italy)

^d UO Ematologia con Talassemia   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^g UNIVERSITY OF FERRARA   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

Author keywords

Bisphosphonates; Bone mineral density; Osteoporosis; Pain; Thalassaemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE BONE ISOENZYME; ANALGESIC AGENT; ASPARTATE AMINOTRANSFERASE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; NERIDRONIC ACID; PARACETAMOL; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BACKACHE; BETA THALASSEMIA; BONE DENSITY; BONE TURNOVER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FLU LIKE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BACK PAIN; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863468463     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09152.x     Document Type: Article

References (53)

1. Adami, S., Gatti, D., Colapietro, F., Fracassi, E., Braga, V., Rossini, M. & Tato, L. (2003) Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research, 18, 126-130.
2. Adami, S., Gatti, D., Bertoldo, F., Sartori, L., Di Munno, O., Filipponi, P., Marcocci, C., Frediani, B., Palummeri, E., Fiore, C.E., Costi, D. & Rossini, M. (2008) Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcified Tissue International, 83, 301-307.
3. Apolone, G. & Mosconi, P. (1998) The Italian SF-36 Health Survey: translation, validation and norming. Journal of Clinical Epidemiology, 51, 1025-1036.
4. Braga, V., Gatti, D., Colapietro, F., Battaglia, E., Righetti, D., Prizzi, R., Rossini, M. & Adami, S. (2003) Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone, 33, 342-345.
5. Canatan, D., Akar, N. & Arcasoy, A. (1995) Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematologica, 93, 20-24.
6. Carmina, E., Di Fede, G., Napoli, N., Renda, G., Vitale, G., Lo Pinto, C., Bruno, D., Malizia, R. & Rini, G.B. (2004) Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcified Tissue International, 74, 68-71.
7. Cascella, T., Musella, T., Orio, Jr, F., Palomba, S., Bifulco, G., Nappi, C., Lombardi, G., Colao, A. & Tauchmanova, L. (2005) Effects of neridronate treatment in elderly women with osteoporosis. Journal of Endocrinological Investigation, 28, 202-208.
8. Cohen, A.R., Galanello, R., Piga, A., De Sanctis, V. & Tricta, F. (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 102, 1583-1587.
9. Compston, J. (2011) Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporosis International, 22, 2951-2961.
10. Corrado, A., Cantatore, F.P., Grano, M. & Colucci, S. (2005) Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clinical Rheumatology, 24, 527-534.
11. Desigan, S., Hall-Craggs, M.A., Ho, C.P., Eliahoo, J. & Porter, J.B. (2006) Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs. Skeletal Radiology, 35, 95-102.
12. Fan, B., Lu, Y., Genant, H., Fuerst, T. & Shepherd, J. (2010) Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems? Osteoporosis International, 21, 1227-1236.
13. Frediani, B., Spreafico, A., Capperucci, C., Chellini, F., Gambera, D., Ferrata, P., Baldi, F., Falsetti, P., Santucci, A., Bocchi, L. & Marcolongo, R. (2004) Long-term effects of neridronate on human osteoblastic cell cultures. Bone, 35, 859-869.
14. Gatti, D., Antoniazzi, F., Prizzi, R., Braga, V., Rossini, M., Tato, L., Viapiana, O. & Adami, S. (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. Journal of Bone and Mineral Research, 20, 758-763.
15. Gatti, D., Viapiana, O., Idolazzi, L., Fracassi, E. & Adami, S. (2009) Neridronic acid for the treatment of bone metabolic diseases. Expert Opinion on Drug Metabolism & Toxicology, 5, 1305-1311.
16. Gaudio, A., Morabito, N., Xourafa, A., Macri, I., Meo, A., Morgante, S., Trifiletti, A., Lasco, A. & Frisina, N. (2008) Bisphosphonates in the treatment of thalassemia-associated osteoporosis. Journal of Endocrinological Investigation, 31, 181-184.
17. Gilfillan, C.P., Strauss, B.J., Rodda, C.P., Bowden, D.K., Kean, A.M., Obaid, M. & Crawford, B.A. (2006) A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcified Tissue International, 79, 138-144.
18. Giusti, A., Hamdy, N.A. & Papapoulos, S.E. (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone, 47, 169-180.
19. Haidar, R., Musallam, K.M. & Taher, A.T. (2011) Bone disease and skeletal complications in patients with beta thalassemia major. Bone, 48, 425-432.
20. Hui, S.L., Gao, S., Zhou, X.H., Johnston, Jr, C.C., Lu, Y., Gluer, C.C., Grampp, S. & Genant, H. (1997) Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. Journal of Bone and Mineral Research, 12, 1463-1470.
21. ICSBM (1997) Standardization of proximal femur bone mineral density (BMD) measurements by DXA. International Committee for Standards in Bone Measurement. Bone, 21, 369-370.
22. Jensen, C.E., Tuck, S.M., Agnew, J.E., Koneru, S., Morris, R.W., Yardumian, A., Prescott, E., Hoffbrand, A.V. & Wonke, B. (1998) High prevalence of low bone mass in thalassaemia major. British Journal of Haematology, 103, 911-915.
23. Johanson, N.A. (1990) Musculoskeletal problems in hemoglobinopathy. Orthopedics Clinics of North America, 21, 191-198.
24. Karimi, M., Ghiam, A.F., Hashemi, A., Alinejad, S., Soweid, M. & Kashef, S. (2007) Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatrics, 44, 29-32.
25. Lasco, A., Morabito, N., Gaudio, A., Buemi, M., Wasniewska, M. & Frisina, N. (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporosis International, 12, 570-575.
26. Leung, T.F., Chu, Y., Lee, V., Cheng, F.W., Leung, W.K., Shing, M.M. & Li, C.K. (2009) Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemoglobin, 33, 361-369.
27. Merlotti, D., Gennari, L., Martini, G., Valleggi, F., De Paola, V., Avanzati, A. & Nuti, R. (2007) Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. Journal of Bone and Mineral Research, 22, 1510-1517.
28. Merlotti, D., Rendina, D., Gennari, L., Mossetti, G., Gianfrancesco, F., Martini, G., De Filippo, G., Avanzati, A., Franci, B., Campagna, M.S., Strazzullo, P. & Nuti, R. (2011) Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone. Journal of Bone and Mineral Research, 26, 512-518.
29. Michelson, J. & Cohen, A. (1988) Incidence and treatment of fractures in thalassemia. Journal of Orthopedic Trauma, 2, 29-32.
30. Morabito, N., Lasco, A., Gaudio, A., Crisafulli, A., Di Pietro, C., Meo, A. & Frisina, N. (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis International, 13, 644-649.
31. Onur, O., Sivri, A., Gumruk, F. & Altay, C. (1999) Beta thalassaemia: a report of 20 children. Clinical Rheumatology, 18, 42-44.
32. Orvieto, R., Leichter, I., Rachmilewitz, E.A. & Margulies, J.Y. (1992) Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcified Tissue International, 50, 397-399.
33. Otrock, Z.K., Azar, S.T., Shamseddeen, W.A., Habr, D., Inati, A., Koussa, S., Mahfouz, R.A. & Taher, A.T. (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Annals of Hematology, 85, 605-609.
34. Perifanis, V., Vyzantiadis, T., Vakalopoulou, S., Tziomalos, K., Garypidou, V., Athanassiou-Metaxa, M. & Harsoulis, F. (2004) Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. British Journal of Haematology, 125, 91-92; author reply 93-94.
35. Perifanis, V., Vyzantiadis, T., Tziomalos, K., Vakalopoulou, S., Garipidou, V., Athanassiou-Metaxa, M. & Harsoulis, F. (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Annals of Hematology, 86, 23-30.
36. Pootrakul, P., Hungsprenges, S., Fucharoen, S., Baylink, D., Thompson, E., English, E., Lee, M., Burnell, J. & Finch, C. (1981) Relation between erythropoiesis and bone metabolism in thalassemia. New England Journal of Medicine, 304, 1470-1473.
37. Shamshirsaz, A.A., Bekheirnia, M.R., Kamgar, M., Pourzahedgilani, N., Bouzari, N., Habibzadeh, M., Hashemi, R., Aghakhani, S., Homayoun, H. & Larijani, B. (2003) Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocrine Disorders, 3, 4.
38. Shamshirsaz, A.A., Bekheirnia, M.R., Kamgar, M., Pakbaz, Z., Tabatabaie, S.M., Bouzari, N., Pourzahedgilani, N., Azarkeivan, A., Hashemi, S.R., Moosavi, F., Alebouyeh, M., Vosough, P., Kimiagar, M., Moradi, M., Habibzadeh, M.R., Nobakhthaghighi, N. & Larijani, B. (2007) Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major. Pediatric Hematology and Oncology, 24, 469-479.
39. Skordis, N., Ioannou, Y.S., Kyriakou, A., Savva, S.C., Efstathiou, E., Savvides, I. & Christou, S. (2008) Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Pediatric Endocrinology Reviews, 6(Suppl 1), 144-148.
40. Trachtenberg, F., Foote, D., Martin, M., Carson, S., Coates, T., Beams, O., Vega, O., Merelles-Pulcini, M., Giardina, P.J., Kleinert, D.A., Kwiatkowski, J., Thompson, A.A., Neufeld, E.J., Schilling, L., Thayalasuthan, V., Pakbaz, Z. & Yamashita, R. (2010) Pain as an emergent issue in thalassemia. American Journal of Hematology, 85, 367-370.
41. Vichinsky, E.P. (1998) The morbidity of bone disease in thalassemia. Annals of the New York Academy of Sciences, 850, 344-348.
42. Vogiatzi, M.G., Autio, K.A., Mait, J.E., Schneider, R., Lesser, M. & Giardina, P.J. (2005) Low bone mineral density in adolescents with beta-thalassemia. Annals of the New York Academy of Sciences, 1054, 462-466.
43. Voskaridou, E. & Terpos, E. (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. British Journal of Haematology, 127, 127-139.
44. Voskaridou, E., Terpos, E., Spina, G., Palermos, J., Rahemtulla, A., Loutradi, A. & Loukopoulos, D. (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. British Journal of Haematology, 123, 730-737.
45. Voskaridou, E., Anagnostopoulos, A., Konstantopoulos, K., Stoupa, E., Spyropoulou, E., Kiamouris, C. & Terpos, E. (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica, 91, 1193-1202.
46. Voskaridou, E., Christoulas, D., Konstantinidou, M., Tsiftsakis, E., Alexakos, P. & Terpos, E. (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica, 93, 1588-1590.
47. Voskaridou, E., Christoulas, D., Xirakia, C., Varvagiannis, K., Boutsikas, G., Bilalis, A., Kastritis, E., Papatheodorou, A. & Terpos, E. (2009) Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica, 94, 725-728.
48. Ware, Jr, J.E. & Sherbourne, C.D. (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473-483.
49. Ware, Jr, J.E., Keller, S.D., Gandek, B., Brazier, J.E. & Sullivan, M. (1995) Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. International Journal of Technology Assessment in Health Care, 11, 525-551.
50. Ware, Jr, J.E., Gandek, B., Kosinski, M., Aaronson, N.K., Apolone, G., Brazier, J., Bullinger, M., Kaasa, S., Leplege, A., Prieto, L., Sullivan, M. & Thunedborg, K. (1998) The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. Journal of Clinical Epidemiology, 51, 1167-1170.
51. Wonke, B. (2001) Clinical management of beta-thalassemia major. Seminars in Hematology, 38, 350-359.
52. Yamaza, T., Masuda, K.F., Atsuta, I., Nishijima, K., Kido, M.A. & Tanaka, T. (2004) Oxidative stress-induced DNA damage in the synovial cells of the temporomandibular joint in the rat. Journal of Dental Research, 83, 619-624.
53. Zografos, G.N., Georgiadou, D., Thomas, D., Kaltsas, G. & Digalakis, M. (2009) Drug-induced esophagitis. Diseases of the Esophagus, 22, 633-637.